High‐Concordance Detection Across Diverse Biospecimens EGFR Mutation in a Large‐Scale NSCLC Cohort Using Droplet Digital PCR and Next‐Generation Sequencing
Accurate detection and quantification of EGFR mutations are essential for molecular stratification in non‐small cell lung cancer (NSCLC). While next‐generation sequencing (NGS) enables comprehensive genomic profiling, droplet digital PCR (ddPCR) offers high sensitivity for predefined mutations. Large‐scale evaluations of ddPCR performance across diverse clinical specimen types remain limited. This retrospective study analyzed 936 analytical mutation‐target records from 747 NSCLC patients with NGS‐detected EGFR mutations. The records represented native DNA or corresponding pre‐capture NGS‐library derivatives from fresh tumor tissue, formalin‐fixed paraffin‐embedded tissue, plasma‐derived cell‐free DNA, and pleural effusion supernatant. ddPCR results were compared with NGS for mutation detection and variant allele frequency quantification using correlation and Bland–Altman analyses. Across all 936 analytical records, ddPCR showed a high overall positive percent agreement (PPA) with NGS (98.82%; 925/936; exact 95% CI, 97.91%–99.41%). Mutation‐specific PPAs were 98.93% for L858R (370/374; exact 95% CI, 97.28%–99.71%), 99.48% for Ex19del (385/387; exact 95% CI, 98.15%–99.94%), and 97.14% for T790M (170/175; exact 95% CI, 93.46%–99.07%). VAFs measured by ddPCR and NGS were strongly correlated (Pearson's
r
= 0.975). Concordance varied by mutation type and sample matrix, with greater variability observed in high‐VAF samples and plasma cfDNA. Paired analyses demonstrated high consistency between native DNA and pre‐capture NGS libraries. ddPCR provides reliable detection and quantification of clinically relevant EGFR mutations across multiple specimen types and processing states. ddPCR represents a practical complement to NGS for EGFR mutation analysis in NSCLC.
A large-scale real-world study demonstrates the heterogeneous molecular landscape of advanced NSCLC and identifies clinically relevant co-alteration patterns involving EGFR, KRAS, STK11, MET, and PIK3CA involving EGFR, which highlight the value of DNA-based NGS profiling for characterizing the genomic landscape and rec...
Aysu Sadioğlu, O. Ekinci, Nalan Akyurek· BMC Cancer· 0 citations
Multiple circulating tumor DNA (ctDNA) platforms are available for KRAS mutation detection in pancreatic ductal adenocarcinoma (PDAC), including broad next-generation sequencing (NGS) and targeted quantitative polymerase chain reaction (qPCR) assays, yet comparisons of performance and concordance are limited. We...
Jennifer Guo, Michael S. May, Michael F. Berger et al.· Cancer Research· 0 citations
Plasma cfDNA analysis is a highly effective, minimally invasive tool for the molecular profiling of lung cancer, particularly when tumor tissue is inaccessible, and the detection of EGFR mutations in clinically suspicious but image negative individuals underscores the predictive validity of liquid biopsy as an early sc...
S. Gurusamy, Saravanan B, B. M. Pabitha Devi et al.· Genetics and Molecular Resea...· 0 citations
Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell l...
F. Knebel, M. F. Ribeiro, R. Linck et al.· Cancer Medicine· 0 citations
Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context, and support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.
N. Karlowatz, L. Kohn, C. Patthey et al.· Frontiers in Oncology· 0 citations
This simple qPCR-based two-gene urine methylation assay provides a scalable, cost-effective and non-invasive complement to PSA-based PCa screening and could safely avert approximately 55% of unnecessary biopsies without compromising cancer detection.
Ding-Wen Liu, Lian Tang, Wei Xiong et al.· Molecular Biomedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.